2 Firms Steer Quest's $450M Cancer Research Firm Buy
Quest Diagnostics announced Thursday a deal to acquire cancer biotechnology firm Haystack Oncology in an all-cash equity deal that could reach $450 million, steered by Weil Gotshal & Manges LLP and...To view the full article, register now.
Already a subscriber? Click here to view full article